Abstract
Background: Overweight is associated with an increased cardiovascular risk which is only partially explained by conventional risk factors. The objective of this study was to evaluate lipoprotein(a) [Lp(a)] plasma levels and apolipoprotein(a) [apo(a)] phenotypes in relation to coronary heart disease (CHD) in overweight subjects. Methods: A total of 275 overweight (BMI ≥ 27 kg/m2) subjects, of which 155 had experienced a CHD event, 337 normal weight subjects with prior CHD and 103 CHD-free normal weight subjects were enrolled in the study. Lp(a) levels were determined by an ELISA technique and apo(a) isoforms were detected by a high-resolution immunoblotting method. Results: Lp(a) levels were similar in the three study groups. Overweight subjects with CHD had Lp(a) concentrations significantly higher than those without [median (interquartile range): 20 (5-50.3) versus 12.6 (2.6-38.6) mg/dl, P <0.05]. Furthermore, overweight subjects with CHD showed a higher prevalence of low molecular weight apo(a) isoforms than those without (55.5% versus 40.8%, P <0.05) and with respect to the control group (55.5% versus 39.8%, P <0.05). Stepwise regression analysis showed that apo(a) phenotypes, but not Lp(a) levels, entered the model as significant independent predictors of CHD in overweight subjects. Conclusions: Our data indicate that small-sized apo(a) isoforms are associated with CHD in overweight subjects. The characterization of apo(a) phenotypes might serve as a reliable biomarker to better assess the overall CHD risk of each subject with elevated BMI, leading to more intensive treatment of modifiable cardiovascular risk factors.
| Original language | English |
|---|---|
| Article number | 12 |
| Journal | BMC Cardiovascular Disorders |
| Volume | 3 |
| DOIs | |
| Publication status | Published - Dec 12 2003 |
Fingerprint
Keywords
- Apolipoprotein(a) isoforms
- Coronary heart disease
- Genetic markers
- Lipoprotein(a) concentration
- Overweight
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Relationship between apolipoprotein(a) size plymorphism and coronary heart disease in overweight subjects. / Emanuele, Enzo; Peros, Emmanouil; Minoretti, Piercarlo; Falcone, Colomba; D'Angelo, Angela; Montagna, Lorenza; Geroldi, Diego.
In: BMC Cardiovascular Disorders, Vol. 3, 12, 12.12.2003.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Relationship between apolipoprotein(a) size plymorphism and coronary heart disease in overweight subjects
AU - Emanuele, Enzo
AU - Peros, Emmanouil
AU - Minoretti, Piercarlo
AU - Falcone, Colomba
AU - D'Angelo, Angela
AU - Montagna, Lorenza
AU - Geroldi, Diego
PY - 2003/12/12
Y1 - 2003/12/12
N2 - Background: Overweight is associated with an increased cardiovascular risk which is only partially explained by conventional risk factors. The objective of this study was to evaluate lipoprotein(a) [Lp(a)] plasma levels and apolipoprotein(a) [apo(a)] phenotypes in relation to coronary heart disease (CHD) in overweight subjects. Methods: A total of 275 overweight (BMI ≥ 27 kg/m2) subjects, of which 155 had experienced a CHD event, 337 normal weight subjects with prior CHD and 103 CHD-free normal weight subjects were enrolled in the study. Lp(a) levels were determined by an ELISA technique and apo(a) isoforms were detected by a high-resolution immunoblotting method. Results: Lp(a) levels were similar in the three study groups. Overweight subjects with CHD had Lp(a) concentrations significantly higher than those without [median (interquartile range): 20 (5-50.3) versus 12.6 (2.6-38.6) mg/dl, P <0.05]. Furthermore, overweight subjects with CHD showed a higher prevalence of low molecular weight apo(a) isoforms than those without (55.5% versus 40.8%, P <0.05) and with respect to the control group (55.5% versus 39.8%, P <0.05). Stepwise regression analysis showed that apo(a) phenotypes, but not Lp(a) levels, entered the model as significant independent predictors of CHD in overweight subjects. Conclusions: Our data indicate that small-sized apo(a) isoforms are associated with CHD in overweight subjects. The characterization of apo(a) phenotypes might serve as a reliable biomarker to better assess the overall CHD risk of each subject with elevated BMI, leading to more intensive treatment of modifiable cardiovascular risk factors.
AB - Background: Overweight is associated with an increased cardiovascular risk which is only partially explained by conventional risk factors. The objective of this study was to evaluate lipoprotein(a) [Lp(a)] plasma levels and apolipoprotein(a) [apo(a)] phenotypes in relation to coronary heart disease (CHD) in overweight subjects. Methods: A total of 275 overweight (BMI ≥ 27 kg/m2) subjects, of which 155 had experienced a CHD event, 337 normal weight subjects with prior CHD and 103 CHD-free normal weight subjects were enrolled in the study. Lp(a) levels were determined by an ELISA technique and apo(a) isoforms were detected by a high-resolution immunoblotting method. Results: Lp(a) levels were similar in the three study groups. Overweight subjects with CHD had Lp(a) concentrations significantly higher than those without [median (interquartile range): 20 (5-50.3) versus 12.6 (2.6-38.6) mg/dl, P <0.05]. Furthermore, overweight subjects with CHD showed a higher prevalence of low molecular weight apo(a) isoforms than those without (55.5% versus 40.8%, P <0.05) and with respect to the control group (55.5% versus 39.8%, P <0.05). Stepwise regression analysis showed that apo(a) phenotypes, but not Lp(a) levels, entered the model as significant independent predictors of CHD in overweight subjects. Conclusions: Our data indicate that small-sized apo(a) isoforms are associated with CHD in overweight subjects. The characterization of apo(a) phenotypes might serve as a reliable biomarker to better assess the overall CHD risk of each subject with elevated BMI, leading to more intensive treatment of modifiable cardiovascular risk factors.
KW - Apolipoprotein(a) isoforms
KW - Coronary heart disease
KW - Genetic markers
KW - Lipoprotein(a) concentration
KW - Overweight
UR - http://www.scopus.com/inward/record.url?scp=3042588235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042588235&partnerID=8YFLogxK
U2 - 10.1186/1471-2261-3-12
DO - 10.1186/1471-2261-3-12
M3 - Article
C2 - 14670093
AN - SCOPUS:3042588235
VL - 3
JO - BMC Cardiovascular Disorders
JF - BMC Cardiovascular Disorders
SN - 1471-2261
M1 - 12
ER -